Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib works in treating patients with extensive
stage small cell lung cancer. Sorafenib may stop the growth of small cell lung cancer by
blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.